Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity.

Ekblad, Eva; Bauer, A J

Published in: Neurogastroenterology and Motility

DOI: 10.1111/j.1743-3150.2004.00487.x

2004

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity

E. EKBLAD* & A. J. BAUER†

*Department of Physiological Sciences, Neuroendocrine Cell Biology, Lund University, Lund, Sweden
†Department of Medicine/Gastroenterology, University of Pittsburgh, Pittsburgh, PA, USA

INTRODUCTION

Enteric neuronal plasticity is an essential adaptive response to various injuries or functional changes within the gastrointestinal tract. It is a complex process involving alterations in neuronal excitability, neurotransmitter expression and/or structural rearrangements. These changes can occur transiently in response to an acute stimulus or become permanently encrypted into the enteric neural circuitry following severe injury or a chronic pathological process. Vasoactive intestinal peptide (VIP) and prostanoids have emerged as important mediators of neuronal plasticity. These mediators are prime examples of the bidirectional communication between the immune and enteric nervous systems. Below we highlight a limited number of studies, which demonstrate the roles of these two mediators in regulating an adaptive plastic response of the enteric nervous system (ENS).

VASOACTIVE INTESTINAL PEPTIDE

Changes in the expression of neurotransmitters have been found to be a common event in neuronal plasticity (for a review see Ekblad et al. 1999). VIP is one of the most readily upregulated transmitters and this occurs during several intestinal pathophysiological situations (Fig. 1), such as blockade of axonal transport by colchicine or axotomy, transplantation or primary culture of isolated ganglia, intestinal surgery and intestinal hypertrophy. An increased VIP expression has also been reported in myenteric ganglia in patients with Crohn’s disease. Recently, VIP given intraperitoneally to mice with trinitro-benzene sulfonic acid (TNBS)-induced colitis reduced the clinical as well as the histopathological signs of the inflammatory response. This was achieved by down-regulating proinflammatory cytokines (tumour necrosis factor [TNF]-α, interleukin [IL]-1β, IL-6 and IL-12) and by increasing the production of the anti-inflammatory agent IL-10. In
addition it is noteworthy that intestinal inflammation induces secretion of cytokines such as IL-1, TNF-α, interferon (IFN)-γ and transforming growth factor (TGF)-β from the myenteric ganglia (the exact identity of the cytokine-secreting cells, neurones or glia, have not yet been established). Taken together, these data suggest an important role for VIP as an anti-inflammatory neuropeptide, denoting that the enteric nervous system can have a profound effect on gastrointestinal immunology.

VIP has also been found to be important in neuroprotection in both central and enteric neurones. In the central nervous system (CNS) the neurotrophic effect of VIP has been suggested to be mediated via release of a variety of cytokines (IL-1α, IL-1β, IL-3, IL-6, TNF-α) chemokines (RANTES and macrophage inflammatory protein-1α) and growth factors such as neurotrophin-3 and activity-dependent neurotrophic factor from astrocytes. VIP has also been shown to release nitric oxide in cocultured rat cerebral cortical cells and glia. Therapeutic administration of VIP or the related pituitary adenylate cyclase-activated peptide (PACAP) after CNS trauma, as well as in neurodegenerative disorders such as Parkinson's disease and multiple sclerosis, has been suggested to possibly prevent neuronal cell death. This suggestion is based on the findings that VIP and PACAP inhibit the production of proinflammatory mediators from activated microglia.

In cultured myenteric neurones both VIP and nitric oxide (NO) promote neuronal survival while VIP antiserum or NO synthase (NOS) inhibition enhance neuronal cell death, indicating that ENS and CNS utilize similar mechanisms for neuroprotection. VIP belongs to a large family of structurally related peptides that also include secretin, growth hormone-releasing factor and PACAP. Like VIP, PACAP is considered an important neurotransmitter within the ENS. Three VIP/PACAP receptors have been cloned: PAC1 with high affinity for PACAP, but with low affinity for VIP,
VPAC₁ and VPAC₂, VPAC₁ and VPAC₂ receptors have approximately equal affinity for both VIP and PACAP. In addition, pharmacological characterization of intestinal VIP/PACAP receptors has revealed the existence of a ‘VIP-specific’ receptor (activated by VIP but not by PACAP) as well as a PACAP-27-prefering receptor.¹⁷ The expression of PACAP is, in analogy to VIP, readily upregulated in enteric neurones in a number of experimental models such as axonal transport blockade by axotomy or colchicine treatment² and during hypertrophic growth of the intestine.³ The VIP/PACAP receptor(s) involved in promoting neuronal survival is still unsettled. In contrast to VIP, PACAP has not been found to promote survival of cultured myenteric neurones.¹⁹ This suggests, as both VPAC₁ and VPAC₂ have a high affinity for both VIP and PACAP while PAC₁ is activated almost exclusively by PACAP, the presence of a ‘VIP-specific’ receptor mediating neuroprotection in adult myenteric neurones. In this context it is notable that an as yet uncharacterized VIP preferring receptor has also been suggested to mediate the VIP-induced cytokine release from astrocytes.¹²

VIP has emerged as a multifactorial enteric neurotransmitter. It has long been recognized as an important neurotransmitter in the ENS for its potential to induce intestinal secretion and relaxation, but now also for its roles in neuroprotection, growth regulation and additionally as a potent anti-inflammatory peptide. The precise mechanisms, by which these various effects of VIP are mechanistically accomplished, are far from understood, but will provide fertile ground for important future studies.

INFLAMMATORY MEDIATORS

Inflammatory modulation of the gastrointestinal nervous system is gradually becoming a well-recognized phenomenon. Various products released from resident and/or infiltrating leucocytes have been demonstrated to sensitize or even directly activate myenteric neurones and intestinal primary afferent neurones. Reactive radicals, such as superoxide, peroxynitrite, lipid peroxide and hydrogen peroxide generated by leucocytes during inflammation or ischaemia, have been shown to alter guinea-pig colonic AH/type-2 myenteric neurones²⁰ as well as cause enteric neuronal damage.²¹ Additionally, reactive radicals have been reported to stimulate afferent splanchnic C fibre units.²²

Resident leucocytes within the gastrointestinal wall, such as mast cells and muscularis macrophages, when activated play a significant role in neuronal plasticity following injury and a changing environment. The mast cell product bradykinin has been shown to facilitate the enteric release of acetylcholine,²³,²⁴ and to increase the excitability of myenteric neurones²⁵ and intestinal primary afferents.²⁶–²⁸ Interestingly, the neuromodulatory effects of bradykinin appear to be mediated in large part through the release of prostanooids²³,²⁴,²⁹,³⁰ via stimulation of the Bk-2 receptor that is coupled to mobilization of both extracellular and intracellular calcium stores in enteric neurones.²⁹

Gradually, evidence is being amassed that indicates that resident muscularis macrophages play an important role in modulating enteric neuromuscular activities. As would be expected of this resident phagocyte, muscularis macrophages are prolific secretors of cytokines, chemokines and mediators that alter motility.³¹–³⁵ The cytokines IL-1β and IL-6, potentially from muscularis macrophages,³⁰,³³,³⁴,³⁶–³⁸ have also been shown to directly enhance the excitability of both AH- and S-type myenteric neurones,³⁹,⁴⁰ decrease the amplitude of fast excitatory postsynaptic potentials⁴⁰ and modulate the enteric release of norepinephrine.⁴¹ It has been shown that TNF binding protein and IL-1 receptor antagonism limits lipopolysaccharide (LPS)-induced iNOS expression within the gut wall, and thus moderates sepsis related ileus.³⁸ Additionally, this treatment, by limiting cytokine–neuronal interactions, could also potentially ameliorate endotoxin induced ileus.

In addition to cytokines, various leucocyte populations involved in the intestinal inflammatory response secrete prostanooids from the highly inducible enzyme cyclooxygenase-2 (COX-2). Cyclooxygenases are key enzymes that produce prostaglandins, catalysing the conversion of arachidonic acid to prostaglandins. Three cyclooxygenase (COX) isoforms have been identified and are referred to as COX-1, COX-2 and COX-3,⁴²,⁴³ COX-1 and COX-3 are produced constitutively, whereas COX-2 is an inducible enzyme known to be upregulated in many inflammatory states.⁴⁴ COX-2 has been shown to be expressed abundantly during sepsis, inflammatory bowel disease, surgery and transplantation.³²,³³,³⁵,⁴⁵–⁴⁷ It follows that this synthase would be induced by reactive radicals, cytokines, and growth factors.⁴⁸ Resident muscularis macrophages, a main leucocyte population involved in the inflammatory response during sepsis and postoperative ileus,³³,³⁷,⁴⁵ secrete significant motility altering amounts of prostaglandins.³⁴,⁴⁵

It has been shown conclusively that prostaglandins, through the induction of COX-2, play a major causative role in initiating and maintaining ileus after intestinal surgery.³³ In this inflamed bowel state
and in others, prostaglandins could hypothetically modulate intestinal motility by four distinct mechanisms. First, prostanoids are proinflammatory and participate in generating the complex inflammatory milieu within the muscularis externa. We have shown that selective COX-2 inhibition given as a pharmacological pretreatment restrains the development of the molecular and cellular inflammatory response within the surgically manipulated muscularis. Secondly, the local generation of prostaglandins within the muscularis by macrophages appears to have a direct inhibitory effect on inflamed smooth muscle contractility, because when COX-2 is acutely inhibited the suppression in circular muscle contractility is relieved from tonic prostanoid inhibition.

The third and fourth proposed mechanisms demonstrate the involvement of prostaglandins in enteric neuronal plasticity and, thus, illustrate an immunoneuronal interaction within the ENS. Given the demonstrated direct smooth muscle effects of prostaglandins during intestinal inflammation, intuitively the ENS and primary afferent nerve endings within the inflamed muscularis would also be exposed to pathological high levels of prostanoids. Hence, the effect of PGE2 has been studied on myenteric and sensory logical high levels of prostanoids. Recently, it has been shown that the acute application of PGE2 depolarizes both AH and S-type colonic neurones with little effect on input resistance or electrical excitability. Prolonged exposure, however, also caused an enhancement in excitability. Hence, these results suggest that PGE2 can play a role in altered motility during inflammatory states by evoking changes in the electrical properties of myenteric neurones. Additionally, prostaglandins have been shown to alter mucosal secretory responses.

Finally, prostaglandins, secreted during inflammation, have been shown to enhance extrinsic primary afferent nerve firing. Again, PGE2 in particular has been demonstrated to have complex effects on primary intestinal afferents. Furthermore, it has been demonstrated that intestinal surgical manipulation of the gut markedly increases spinal c-fos expression for a prolonged period postoperatively and that COX-2 inhibition significantly diminishes this prolonged increase in primary afferent activity. It has been hypothesized that this reflects heightened local primary afferent activation, which would initiate subsequently sympathetic inhibitory motor reflexes to the gut, leading to an immunoneuronal component of inflammatory mediated ileus. Thus, these data demonstrate that prostaglandins generated by the inducible COX-2 provide a crucial link between intestinal inflammatory mechanisms and the development of neuroplastic responses within the inflamed gut wall.

CONCLUDING REMARKS

Gastrointestinal dysfunction, which often has a component of dysmotility, accompanies most gastrointestinal diseases. Gastrointestinal activities are controlled, to a great extent, by enteric nerves and thus many functional bowel disorders probably have their origin in neuropathological changes of the ENS. We are gradually acquiring a fairly good understanding of ENS organization and function, and even though it belongs to the autonomic nervous system it strikingly resembles the CNS in neurochemistry, neuronal circuitry, mechanisms for long-term potentiation, glial elements and lack of collagen. By analogy with CNS neurological disorders, it may be expected that the ENS will also malfunction and be mechanistically at the root of various gastrointestinal diseases, and accumulating evidence supports this hypothesis. Hence, the pathogenesis and pathophysiology of several gastrointestinal disorders are suggested to involve injury- or inflammation-induced neurodegeneration. In response to and in order to counteract these various injurious mechanisms, the ENS has developed adaptive plasticity and neuroprotective mechanisms as key features to maintain intestinal function. Advancements in our knowledge on the identity, role and regulation of the various mediators involved in plasticity and protection will undoubtedly be followed by clinical applications.

REFERENCES

4. Schwarz NT, Tweardy DJ, Billiar TR, Bauer AJ. Interleukin-6 mediates an increase in VIP mRNA within the jejunal muscularis: a neural mechanism for postoperative ileus. Neurogastroenterol Motil 1999; 11: 288.
VIP and inflammatory mediators in enteric neuronal plasticity


38 Lodato RF, Khan AR, Zembowicz MJ et al. Roles of IL-1 and TNF in the decreased ileal muscle contractility induced by lipopolysaccharide. Am J Physiol Gastrointest Liver Physiol 1999; 276: G1356–62.


